Tagged with B

Colombia Tecnoquimicas (TQ), the largest domestic player in Colombia’s USD 4.6 billion pharma market, announced a swathe of manufacturing investments in late 2019, taking its spending on plants and equipment in the 2018-2022 period to over USD 200 million.   According to Company President Francisco José Barberi, TQ’s investments will expand…

Germany Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital Healthcare Act, the impact of the coronavirus outbreak on investor sentiment, and the health minister potentially poised to become Germany’s…

UK Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get Brexit Done”.   The UK now enters an 11-month transition period to disentangle political and economic ties from a single…

Belgium Over the past few decades, pharma multinationals have been increasingly drawn to the highly cost-competitive markets of Central Eastern Europe (CEE) and Asia to situate major manufacturing sites. However, despite a comparatively expensive location, Belgium’s strong industrial heritage and manufacturing expertise is helping to maintain the country as a strategic…

Belgium Paul Herijgers, dean of the faculty of medicine at leading Belgian university KU Leuven, outlines the collaborative research projects the university is undertaking and its role within the wider Belgian innovation ecosystem.   [KU Leuven] is actually the most innovative university in Europe according to Reuters Rankings thanks to our…

Romania Valentina Băicuianu and Adrian Grecu of the APMGR, share their insights on the deteriorating environment for generics in Romania, with unfavourable pricing methodology and a rising and an unpredictable clawback tax. They reveal the solutions that the generics industry has proposed to authorities and outline their continued endeavours to convince…

Czech Republic Martin Minarovič, Janssen’s country director Czech Republic, discusses the success factors behind the company’s strong growth, not only in terms of revenue but more importantly in terms of the number of patients treated. Moreover, he highlights Janssen’s transformation to become a more customer- and patient-centric organization, the progress and areas…

Generics Arun Narayan of Medicines for Europe’s Value Added Medicines Group has been working to promote the benefits of value added medicines and how real-world evidence must be considered. In a recent interview with PharmaBoardroom he elaborated on what some countries are already doing to adopt Value Added Medicines and the…

Belgium There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without a reversal of current trends. Against this backdrop, the European Commission is launching the ‘Europe’s Beating Cancer Plan’ to reduce…

Czech Republic Ladislav Drož, CEO of APIGENEX, reveals the company’s strategy to survive after a leadership change and a reshuffling of the small-molecule science operations at their main client, Novo Nordisk. Drož also discusses APIGENEX’s future goals of investing in robotics and automation. APIGENEX’s services include chemistry, experimental pharmacology, clinical pharmacology, registration…

Czech Republic Patrik Reichl, CEO of CzechInvest, the Investment and Business Development Agency under the Ministry of Industry and Trade of the Czech Republic, breaks down the role of the agency in implementing the Innovation Strategy 2019–2030 and transforming the Czech Republic as the “Country for the Future” by fostering a local…

Belgium Joris Van Assche, managing director of the Belgian association for accessible medicines, Medaxes, highlights the need for a stronger policy to create a more positive environment for generic and biosimilar medicines. He also outlines the important role the off-patent sector plays in the long-term sustainability of Belgium’s universal healthcare system.…